Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7723690 | 1.00 | ACACB (0.54) | ACACBACACA | |
| SCHEMBL7010951 | 0.87 | MMP9 (0.50) | ACACBACACA | |
| SCHEMBL30202565 | 0.86 | ACACB (0.50) | ACACBACACA | |
| SCHEMBL20791689 | 0.85 | L3MBTL1 (0.53) | — | |
| SCHEMBL13778592 | 0.85 | ACACB (0.56) | ACACBACACA | |
| SCHEMBL20791688 | 0.85 | L3MBTL1 (0.53) | — | |
| SCHEMBL10315770 | 0.84 | L3MBTL1 (0.45) | — | |
| SCHEMBL6966307 | 0.83 | ACACB (0.54) | ACACBACACA | |
| SCHEMBL15022611 | 0.83 | ACACB (0.54) | ACACBACACA | |
| SCHEMBL5987917 | 0.82 | ACACB (0.54) | ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180194762-A1 | PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2018-07-12 | — | — | US | disclosed |
| WO-2014114578-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-31 | — | — | WO | disclosed |
| US-7592488-B2 | Method for preparing optically active amines | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2009-09-22 | — | — | US | disclosed |
| US-7592488-B2 | Method for preparing optically active amines | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2009-09-22 | — | — | US | disclosed |
| US-20090035830-A1 | Method for Preparing Optically Active Amines | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2009-02-05 | — | — | US | disclosed |
| US-20090035830-A1 | Method for Preparing Optically Active Amines | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2009-02-05 | — | — | US | disclosed |
| WO-2008027740-A2 | CATALYTIC ASYMMETRIC SYNTHESIS OF PRIMARY AMINES VIA BORANE REDUCTION OF OXIME ETHERS USING SPIROBORATE ESTERS | OFFICE OF INTELLECTUAL PROPERTY AND TECHNOLOGY (US) | 2008-03-06 | — | — | WO | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| US-20030203946-A1 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194762-A1 | PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LCK | ACACB 2586/4885ACACA 3798/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | ACACB 3883/4885ACACA 3773/4885 |
| US-20030203946-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | ACACB 591/4885ACACA 338/4885 |
| US-20090035830-A1 | Method for Preparing Optically Active Amines | CEL, NAAA, LIPA | ACACB 339/4885ACACA 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.